Trevena, Inc. (TRVN) - Forward P/S Multiple
The implementation of ESG standards and sustainable production cycles is positively impacting the price action of Trevena, Inc. (TRVN). The forward price-to-revenue ratio demonstrates stability due to protected distribution channels for neuropreparations, although a critical liquidity deficit and the risk of business cessation are creating pressure. The current value is fixed at 4.80, highlighting the fragile balance between operational profitability and the threat of a total shutdown of activities.
Analytical breakdowns for Trevena, Inc.
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Trevena, Inc.|TRVN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Trevena, Inc.|TRVN - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Trevena Inc|TRVN - Company Long-Term Loans and Borrowings|Company Current Liabilities Trevena|Quick Liquidity trevena.com
- business earnings and investment ratios data:
TRVN - Company Profit|Expected Profit Trevena, Inc.|TRVN - Price to Earnings Multiple|Forward P/E Multiple Trevena, Inc|TRVN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Trevena Inc|TRVN - Operating profit EBITDA|Earnings per share for the last twelve months Trevena|TRVN - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months trevena.com|TRVN - Earnings per share growth rate in current year|Expected earnings per share growth for next year Trevena, Inc.
- sales and revenue indicators:
General company analysis:TRVN (Trevena)
The forward P/S reflects the market value of Trevena, Inc. (TRVN) relative to expected revenue, allowing for an assessment of the asset's overvaluation against future cash flows. Analyzing the forward P/S chart for Trevena, Inc. (TRVN), an investor may observe how geopolitical instability and sanction restrictions hindering the certification of neurological drugs create risks of business revaluation should clinical trial deadlines be missed.
Key competitors
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Market Cap to Expected Sales Ratio Denali Corp|Harmony Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BHVN (biohavenpharma.com)|AMLX - Price-to-Projected Revenue Ratio|Forward Price to Sales TRVI (Trevi Therapeutics Inc)|PRAX (Praxis Medicines) - Forward Price-to-Revenue Multiple|AVXL (Anavex Life Sciences Corp) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio CeriBell, Inc.|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|Annexon Biosciences - Market Cap to Projected Revenue|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR - Forward P/S Multiple|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding - Forward Price to Sales|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Market Cap to Future Revenue Ratio Alpha Cognition Corp ACOG|Forward Price-to-Revenue Multiple CGTX (Cognition Therapeutics)|Price to Expected Revenue Ratio IKT|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Forward Price to Sales ASRT|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|ABOS (acumenpharm.com) - Price-to-Projected Revenue Ratio|CRVO (CervoMed) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Alterity Therapeutics Ltd ATHE|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|pepgen.com - Market Cap to Projected Revenue|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|Forward P/S Multiple relmada.com RLMD|ANVS: Forward Price-to-Revenue Multiple|Forward Price to Sales GRCE (Grace Therapeutics, Inc.)|AIFF: Forward P/S Multiple|KLTO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|Market Cap to Projected Revenue RVPH (revivapharma.com)|Forward P/S Multiple MTVA|Forward Price-to-Revenue Multiple NeurAxis Inc. NRXS|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Passage Bio Inc. (PASG)|NEUP: Forward Price-to-Revenue Multiple|minervaneurosciences.com - Price to Expected Revenue Ratio|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics Ltd. - Forward Price to Sales|Forward Price-to-Revenue Multiple ALZN|Price-to-Projected Revenue Ratio CYCN|Price-to-Projected Revenue Ratio Protagenic Therapeutics (PTIX)|pasitheaclinics.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Cortigent CRGT|ATXI: Market Cap to Projected Revenue|Brainstorm Cell Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Cara Therapeutics Inc|CHRO (Chromocell Therapeutics) - Forward Price-to-Revenue Multiple|Eliem Therapeutics Inc. (ELYM) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Intra-Cellular Therapies Inc.|LBPH: Forward Price to Sales|Price-to-Projected Revenue Ratio Marinus (MRNS)|NKGN - Market Cap to Future Revenue Ratio|NeuroBo Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio SAGE (sagerx.com)|SNPX - Price-to-Projected Revenue Ratio|Forward Price to Sales VIGL (Vigil Neuroscience)|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
